OM:BIOA BBiotechs
How Leqembi’s China Insurance Listing At BioArctic (OM:BIOA B) Has Changed Its Investment Story
BioArctic’s partner Eisai has announced that Alzheimer’s drug Leqembi (lecanemab) has been added to China’s National Healthcare Security Administration “Commercial Insurance Innovative Drug List,” expanding access to early Alzheimer’s treatment in a key market following its June 2024 launch there.
This move materially enhances the commercial potential of Leqembi in China, which could be important for BioArctic given its role in the drug’s development and its ongoing commercialization...